Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Inclusion Criteria: * Healthy male or female subjects between 18 and 65 years of age inclusive with body weight \>= 50 kg and body mass index (BMI) within the range 19 to 32 kilogram/meter squared * Alanine aminotransferase (ALT) alkaline phosphatase and bilirubin \<or=1.5x upper limit of normal (ULN). * Normal ECG measurements. Average QT duration corrected for heart rate by Fridericia's formula (QTcF) \<450 millisecond or QTcF \<480 msec in subjects with Bundle Branch Block based on an average from three electrocardiograms (ECGs) obtained over a brief recording period. * Female subjects of non-child bearing potential. Females of child bearing potential are eligible to enter if they are not pregnant and willing to use protocol-specified methods of contraception to prevent pregnancy until 14 days post-last dose of metformin/glimepiride. * Capable of giving written informed consent Exclusion Criteria: * The subject has a positive: drug/alcohol screen, Hepatitis, HIV screen * Abuse of alcohol * Current or chronic history of liver disease, or known hepatic or biliary abnormalities * Exposure to more than four new investigational chemical entities within 12 months prior to the first dosing day * Participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) * Sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation * Donation of more than 500 mL blood within a 56 day period * Pregnant or lactating females * Unwillingness or inability to follow the procedures outlined in the protocol * Subject is mentally or legally incapacitated * Subject having positive urinary cotinine levels indicative of use of tobacco or nicotine-containing products within 6 months prior to screening. * Unable to refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose * Subjects having asthma or are positive carbon monoxide (CO) on admission to the Unit * Unable to refrain from the use of prescription or non-prescription drugs within 7 days prior to first dose of study medication, unless approved by the Investigator and GSK Medical Monitor.